Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

The primary-source earnings evidence improves the prior neutral monitoring thesis, consistent with the positive deterministic prior, but the initial market response was modest: RF rose $0.14, or 0.51%, to $27.45 on October 16. The verified consensus comparison indicates an adjusted EPS beat; revenue-surprise framing varies across secondary sources, so it is not used as a positive catalyst. No verified post-print analyst target or estimate revision was found, and social context is unavailable. [Company investor relations](https://ir.regions.com/home/default.aspx) [Price history](https://stockanalysis.com/stocks/rf/history/)

Low coverage and no confirmed October earnings print prevent a defensible post-release price-reaction or analyst-revision assessment. The $68.30 October 16 anchor is a pre-confirmation reference, not evidence of an earnings reaction. Sentiment metrics other than low observed headline buzz are unavailable; zero values denote unavailable data, not neutral readings. The strong second-quarter primary-source evidence supports monitoring, while the negative deterministic directional prior and unresolved earnings trigger argue against upgrading the thesis. [Company IR](https://ir.psbt.com/investor-resources/press-releases/default.aspx)

Post-print tone is mixed: company-reported growth and raised guidance met a modest revenue miss and mostly downward target revisions among the three reported by Benzinga. Packet coverage reported an initial share decline near 4%; Benzinga reported $165.60 on October 15, close to RankAlpha's $165.72 October 16 anchor, so the initial selloff had not clearly reversed. The deterministic prior remains negative despite a meaningful thesis update (change score 0.685). Social, options, short-interest and employee readings are unavailable; zero fields are placeholders, not observations. https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62388328/these-analysts-revise-their-forecasts-on-state-street-after-q3-results

The confirmed operating EPS beat was small—$5.08 versus Zacks' $4.98 consensus—and MTB closed the release day down 1.54%. The packet's stored earnings-document rows are pre-release third-party articles, not MTB releases; the company release and 8-K exhibit supply the operating evidence. Verified post-print analyst revisions and a sufficiently sourced social or options signal are unavailable. The positive deterministic prior reflects a real Q3 thesis update, but the adverse price response and limited revision evidence warrant measured confidence. [Company release](https://newsroom.mtb.com/2026-10-16-M-T-Bank-Corporation-NYSE-MTB-announces-third-quarter-2026-results); [consensus comparison](https://www.zacks.com/stock/news/3009166/mt-bank-corporation-mtb-q3-earnings-and-revenues-top-estimates); [closing price](https://stockanalysis.com/stocks/mtb/history/).

Neutral, low-coverage monitoring view. The October 16 closing anchor was $17.52, but there is no confirmed earnings release from that date and no defensible post-earnings price reaction to attribute. No post-print analyst target or estimate revisions were found; absence is not a positive signal. Sentiment fields set to zero indicate unavailable measurements, not observed neutral readings. The October 16 filing instead documents finance-officer changes. [#8-K-2026-10-16]

This is a pre-Q3 monitoring view, not a post-earnings reaction: the company scheduled results for October 27. The $65 October 16 anchor therefore cannot establish a Q3 post-release price move. Q2 primary-source evidence is mixed. Verified post-Q3 analyst revisions, immediate market reaction, and measured news, social, options, short-interest and employee sentiment are unavailable; zero sentiment fields denote missing measurements, not neutral readings. [Company announcement](https://ir.euronetworldwide.com/news-releases/news-release-details/euronet-announces-third-quarter-earnings-release-date-and)